Completed PHASE1 INTERVENTIONAL NCT00370006

Phase 1 Trial of CMV Towne Vaccine in Subjects Previously Received VCL CT02 Vaccine ID or IM

A Phase 1 Clinical Trial to Evaluate the Safety of, and Kinetics and Magnitude of the CMV-Specific Immune Response to, Challenge With a Live Attenuated Strain of CMV (Towne) in Healthy, CMV- Seronegative, Adult Subjects Who Previously Received a CMV Immunotherapeutic Trivalent pDNA Vaccine (VCL CT02) Administered Intradermally or Intramuscularly

Sponsor: University of California, San Francisco

Conditions Cytomegalovirus Infection

Interventions Towne CMV vaccine

Updated 5 times since 2017 Last updated: Jan 10, 2007 Started: Sep 30, 2006 Completion: Aug 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Cytomegalovirus Infection, this trial is completed. The trial is conducted by University of California, San Francisco and has accumulated 5 data snapshots since 2006. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Sep 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of California, San Francisco
Vical

Data source: University of California, San Francisco

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.